Dear Editor: I read with great interest the recent article by Buttar et al1 detailing fatal consequences of the chronic neuroleptic malignant syndrome (NMS) from the United States. The authors
This ongoing column is dedicated to providing information to our readers on managing legal risks associated with medical practice. We invite questions from our readers. The answers are provided by
by Charles D. Cash, JD, LLM Mr. Cash is Senior Risk Manager for Professional Risk Management Services, Inc., Arlington, Virginia. Innov Clin Neurosci. 2011;8(9):26–30
